By Dr Brittney Harrington

Journal articles

Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM, 2024, 'Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer', Cancer Gene Therapy, 31, pp. 721 - 735, http://dx.doi.org/10.1038/s41417-024-00748-w

Harrington BS; Kamdar R; Ning F; Korrapati S; Caminear MW; Hernandez LF; Butcher D; Edmondson EF; Traficante N; Hendley J; Gough M; Rogers R; Lourie R; Shetty J; Tran B; Elloumi F; Abdelmaksoud A; Nag ML; Mazan-Mamczarz K; House CD; Hooper JD; Annunziata CM, 2023, 'UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer', Journal of Experimental and Clinical Cancer Research, 42, http://dx.doi.org/10.1186/s13046-023-02820-z

Kamdar RD; Harrington BS; Attar E; Korrapati S; Shetty J; Zhao Y; Tran B; Wong N; House CD; Annunziata CM, 2023, 'NF-κB Signaling Modulates miR-452-5p and miR-335-5p Expression to Functionally Decrease Epithelial Ovarian Cancer Progression in Tumor-Initiating Cells', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms24097826

Caminear MW; Harrington BS; Kamdar RD; Kruhlak MJ; Annunziata CM, 2022, 'Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells', Frontiers in Oncology, 12, http://dx.doi.org/10.3389/fonc.2022.762820

Kryza T; Khan T; Lovell S; Harrington BS; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala JK; Dreyer T; Magdolen V; Reuning U; He Y; Tate EW; Hooper JD, 2021, 'Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1', Nature Chemical Biology, 17, pp. 776 - 783, http://dx.doi.org/10.1038/s41589-021-00783-w

Harrington BS; Ozaki MK; Caminear MW; Hernandez LF; Jordan E; Kalinowski NJ; Goldlust IS; Guha R; Ferrer M; Thomas C; Shetty J; Tran B; Wong N; House CD; Annunziata CM, 2020, 'Drugs targeting tumor-initiating cells prolong survival in a post-surgery, post-chemotherapy ovarian cancer relapse model', Cancers, 12, pp. 1 - 21, http://dx.doi.org/10.3390/cancers12061645

Khan T; He Y; Kryza T; Harrington BS; Gunter JH; Sullivan MA; Cuda T; Rogers R; Davies CM; Broomfield A; Gough M; Wu AC; McGann T; Weroha SJ; Haluska P; Forbes JM; Armes JE; Barry SC; Coward JI; Jagasia N; Chetty N; Snell CE; Lourie R; Perrin LC; Hooper JD, 2020, 'Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma', Cancers, 12, http://dx.doi.org/10.3390/cancers12040869

He Y; Davies CM; Harrington BS; Hellmers L; Sheng Y; Broomfield A; McGann T; Bastick K; Zhong L; Wu A; Maresh G; McChesney S; Yau Wong K; Adams MN; Sullivan RC; Palmer JS; Burke LJ; Ewing AD; Zhang X; Margolin D; Li L; Lourie R; Matsika A; Srinivasan B; McGuckin MA; Lumley JW; Hooper JD, 2020, 'CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin', Oncogene, 39, pp. 219 - 233, http://dx.doi.org/10.1038/s41388-019-0983-3

Harrington BS; He Y; Khan T; Puttick S; Conroy PJ; Kryza T; Cuda T; Sokolowski KA; Tse BWC; Robbins KK; Arachchige BJ; Stehbens SJ; Pollock PM; Reed S; Weroha SJ; Haluska P; Salomon C; Lourie R; Perrin LC; Law RHP; Whisstock JC; Hooper JD, 2020, 'Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer', Theranostics, 10, pp. 2095 - 2114, http://dx.doi.org/10.7150/thno.30736

Harrington BS; Annunziata CM, 2019, 'Nf-κb signaling in ovarian cancer', Cancers, 11, http://dx.doi.org/10.3390/cancers11081182

He Y; Reid JC; He H; Harrington BS; Finlayson B; Khan T; Hooper JD, 2018, 'Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1', Biological Chemistry, 399, pp. 1091 - 1097, http://dx.doi.org/10.1515/hsz-2017-0308

Chen Y; Harrington BS; Lau KCN; Burke LJ; He Y; Iconomou M; Palmer JS; Meade B; Lumley JW; Hooper JD, 2017, 'Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens', Journal of Pharmaceutical and Biomedical Analysis, 139, pp. 65 - 72, http://dx.doi.org/10.1016/j.jpba.2017.02.047

Oancea I; Movva R; Das I; Aguirre De Cárcer D; Schreiber V; Yang Y; Purdon A; Harrington B; Proctor M; Wang R; Sheng Y; Lobb M; Lourie R; Cuív PO; Duley JA; Begun J; Florin THJ, 2017, 'Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism', Gut, 66, pp. 59 - 69, http://dx.doi.org/10.1136/gutjnl-2015-310874

Wu AC; He Y; Broomfield A; Paatan NJ; Harrington BS; Tseng HW; Beaven EA; Kiernan DM; Swindle P; Clubb AB; Levesque JP; Winkler IG; Ling MT; Srinivasan B; Hooper JD; Pettit AR, 2016, 'CD169⁺ macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer', Journal of Pathology, 239, pp. 218 - 230, http://dx.doi.org/10.1002/path.4718

Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; De Fazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD, 2016, 'Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer', British Journal of Cancer, 114, pp. 417 - 426, http://dx.doi.org/10.1038/bjc.2015.471

He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD, 2016, 'Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance', Oncogene, 35, pp. 468 - 478, http://dx.doi.org/10.1038/onc.2015.101

He Y; Harrington BS; Hooper JD, 2016, 'New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways', Oncoscience, 3, pp. 5 - 8, http://dx.doi.org/10.18632/oncoscience.286

Pinder A; Loo D; Harrington B; Oakes V; Hill MM; Gabrielli B, 2015, 'JIP4 is a PLK1 binding protein that regulates p38MAPK activity in G2 phase', Cellular Signalling, 27, pp. 2296 - 2303, http://dx.doi.org/10.1016/j.cellsig.2015.08.009

Adams MN; Harrington BS; He Y; Davies CM; Wallace SJ; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD, 2015, 'EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface', Oncogene, 34, pp. 1375 - 1383, http://dx.doi.org/10.1038/onc.2014.88

Oakes V; Wang W; Harrington B; Lee WJ; Beamish H; Chia KM; Pinder A; Goto H; Inagaki M; Pavey S; Gabrielli B, 2014, 'Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle', Cell Cycle, 13, pp. 3302 - 3311, http://dx.doi.org/10.4161/15384101.2014.949111

Dong Y; Harrington BS; Adams MN; Wortmann A; Stephenson SA; Lisle J; Herington A; Hooper JD; Clements JA, 2014, 'Activation of membrane-bound proteins and receptor systems: A link between tissue kallikrein and the KLK-related peptidases', Biological Chemistry, 395, pp. 977 - 990, http://dx.doi.org/10.1515/hsz-2014-0147

Back to profile page